New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally. January 13, 2020 – Philadelphia, PA – WuXi Advanced...
SHANGHAI and SEOUL, South Korea, Nov. 28, 2019 /PRNewswire/ — WuXi ATU Co., Ltd., (WuXi ATU) – a subsidiary of WuXi AppTec, and GeneMedicine – a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the...
San Francisco and Philadelphia – November 6, 2019 — Vineti, a leading provider of a digital platform of record for personalized therapies, and WuXi AppTec Advanced Therapies, a Contract Development and Manufacturing Organization (CDMO) have entered into a...
Partnership combines global CDMO services with industry leading cellular orchestration platform Cardiff, UK & Philadelphia, PA, October 1, 2019 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems and WuXi...
Philadelphia, PA. – May 31, 2019 – Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology has expanded its relationship with WuXi AppTec’s Advanced Therapies Business...
The new facility will more than double testing capacity for cell and gene therapies. On November 1, 2018, Liberty Property Trust and Synterra Partners held a groundbreaking ceremony to kick off the construction of our fourth building in the Philadelphia Navy Yard. The...
